

July 19, 2019

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Product Registration in Cambodia

Ref.: Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that we, Zota Health Care Limited (the "Company") have received product registration licenses for below mentioned 3 products from Ministry of Health, Cambodia.

Sr. No.	Name of Product	Therapeutic Category
1	ZOMEPE – 20 (Cap – Each Capsule contains Omeprazole 20mg)	PPI (Proton Pump Inhibitor)
2	Gastrosafe Kit [Each combikit contains Lansoprazole (2 .Caps), Clarithromycin (2 Tabs.) & Tinidazole (2 Tabs.)]	Combiner's Kit for GI Infection
3	TAMZED 0.4 (Cap – Each Capsule contains Tamsulosin Hydrochloride 0.4 mg)	Alpha - Adrenergic blocker

We have received licenses for the aforementioned products for the period of five years and the same shall be expired on 09-05-2024, licenses for the products are also renewable. Company shall start exporting this product in Cambodia very soon.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**



Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat



Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122